Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Comment by MrVerbatim9800on Dec 15, 2020 2:08pm
331 Views
Post# 32110367

RE:RE:RE:RE:They get 1 share and one half share warrant for the $4.40

RE:RE:RE:RE:They get 1 share and one half share warrant for the $4.40I'm not trying to be argumentative here, but when Cannacord is involved, this volume can definitely continue until the balance is attained. The last thing they want is for MMED to loose a foothold and momentum at this point. It only makes sense to have a strong presence to compete with others on the NASDQ. Especially with their rival (SHRM) To resume trading soon.
Silentbull wrote: This volume is not sustainable, once it dries a daily slow bleed has to bring down the price, no doubts bout that. Some one asked about $3.75, all i say is price never goes up and down in a straight line, look at the chart in next 45-60 days and decide what was shared with you was correct or incorrect


<< Previous
Bullboard Posts
Next >>